Headlands Research, a global next-generation clinical research site organization, has acquired Summit Research Network in Portland, Oregon. The acquisition follows Headlands’ recent addition of Artemis Institute for Clinical Research in February. Coupled with the new acquisition, Headlands Research also launched its fourth Horizons site in Scottsdale, AZ.
Summit Research Network is focused on improving medical treatment by conducting high quality scientific research and patient care. Summit Research Network specializes in the areas of psychiatry, dementia and other age-related memory conditions such as Alzheimer’s and Lewy Bodies, and operates a specialized memory health center.
“Summit’s depth of experience in our industry is unparalleled,” said Mark Blumling, CEO and founder of Headlands Research. “We are very excited to have Summit’s forty-five years of seasoned clinical trial research expertise joining our mission to meaningfully impact the clinical trials process and to be an industry leader in patient recruitment diversity.”
“We are delighted to be joining Headlands Research and their impressive global network of clinical trial research sites that are scaling at a rapid pace,” said James Hockley, president of Summit Research Network. “We share a common vision to make a positive impact in the clinical trials process, enrich diversity, improve patient care, and drive scientific knowledge forward in the industry. After learning more about their mission, leadership and competencies, it was clear to see the natural fit and how both organizations can accelerate the collective impact we can have on the clinical trials process.”
“By extending our platform footprint to the Southwest, the Scottsdale Horizons Site is an important geographical expansion of Headlands, but most importantly, it is representative of Headlands’ continued commitment and focus on patient diversity,” added Blumling.